within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX22_LoncastuximabTesirine;

model LoncastuximabTesirine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 6.064814814814815e-09,
    adminDuration = 600,
    adminMass = 150 / 1000000,
    adminCount = 1,
    Vd = 0.00711,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00617,
    k12 = 8.067129629629628e-09,
    k21 = 8.067129629629628e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>LoncastuximabTesirine</td></tr><tr><td>ATC code:</td><td>L01FX22</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>150</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>7.11</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.524</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Loncastuximab tesirine is an antibody-drug conjugate (ADC) composed of a CD19-directed monoclonal antibody conjugated to a cytotoxic pyrrolobenzodiazepine dimer. It is approved for use in adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with relapsed or refractory diffuse large B-cell lymphoma. Data are based on population PK analysis of clinical trial subjects.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01FX22 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end LoncastuximabTesirine;
